EssilorLuxottica/€EL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About EssilorLuxottica
EssilorLuxottica is a French-Italian multinational corporation operating in the eyewear and eye care industry. It was formed through the merger of the French ophthalmic optics company Essilor and the Italian eyewear company Luxottica in 2018. The company designs, manufactures, and distributes ophthalmic lenses, optical equipment, and eyewear, including well-known brands such as Ray-Ban, Oakley, and Persol, as well as licensed brands like Chanel and Prada. Headquartered in Charenton-le-Pont, France, and Milan, Italy, EssilorLuxottica has a global presence with operations in over 150 countries. Its strategic positioning is underscored by its integrated business model that encompasses both retail and wholesale distribution, leveraging its extensive portfolio of proprietary and licensed brands.
- Ticker
- €EL
- Sector
- Health
- Primary listing
- PAR
- Employees
- 213,909
- Headquarters
- Paris, France
- Website
- www.essilorluxottica.com
EssilorLuxottica Metrics
BasicAdvanced
€66B
26.90
€5.35
0.55
€4.00
2.78%
Price and volume
Market cap
€66B
Beta
0.55
52-week high
€322.60
52-week low
€138.00
Average daily volume
832K
Dividend rate
€4.00
Financial strength
Current ratio
0.889
Quick ratio
0.499
Long term debt to equity
0.242
Total debt to equity
0.384
Dividend payout ratio (TTM)
66.92%
Interest coverage (TTM)
10.55%
Profitability
EBITDA (TTM)
5,899
Gross margin (TTM)
60.03%
Net profit margin (TTM)
8.52%
Operating margin (TTM)
12.82%
Effective tax rate (TTM)
23.99%
Revenue per employee (TTM)
€140,000
Management effectiveness
Return on assets (TTM)
3.71%
Return on equity (TTM)
6.72%
Valuation
Price to earnings (TTM)
26.899
Price to revenue (TTM)
2.268
Price to book
1.7
Price to tangible book (TTM)
-28.64
Price to free cash flow (TTM)
17.291
Free cash flow yield (TTM)
5.78%
Free cash flow per share (TTM)
8.325
Dividend yield (TTM)
2.78%
Forward dividend yield
2.78%
Growth
Revenue change (TTM)
7.50%
Earnings per share change (TTM)
3.85%
3-year revenue growth (CAGR)
4.93%
10-year revenue growth (CAGR)
15.57%
3-year earnings per share growth (CAGR)
0.81%
10-year earnings per share growth (CAGR)
3.98%
3-year dividend per share growth (CAGR)
7.39%
10-year dividend per share growth (CAGR)
13.68%
What the Analysts think about EssilorLuxottica
Analyst ratings (Buy, Hold, Sell) for EssilorLuxottica stock.
Analyst projections of the future price of EssilorLuxottica stock.
Bulls say / Bears say
First-half revenue rose 9.7% at constant exchange rates, while adjusted operating profit climbed 15%. The profit increase beat forecasts, though tariff refunds helped lift it. (Reuters)
AI-glasses revenue nearly doubled in the second quarter, and EssilorLuxottica and Meta are widening the range and rolling it out to more markets. That gives the group a fast-growing product line beyond traditional eyewear. (Bloomberg, EssilorLuxottica)
Its myopia-management portfolio grew 24% in the second quarter, adding a distinct growth engine alongside eyewear and smart glasses. (EssilorLuxottica)
Second-quarter revenue growth slowed to 8.7% and missed analysts’ expectations, with Bloomberg linking the weaker result to global economic uncertainty. That raises the risk that demand is softening even as the company expands. (Bloomberg)
EssilorLuxottica faces stronger competition in smart glasses as other technology groups enter the market. That could make it harder to sustain its early lead and the growth investors expect. (Reuters)
Ray-Ban Meta glasses are less profitable than the group’s core eyewear, and investors are pressing the company to show it can scale sales without giving up margins. If growth relies increasingly on these products, profitability could come under pressure. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2026.
EssilorLuxottica Financial Performance
Revenues and expenses
EssilorLuxottica Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing EssilorLuxottica
AllEURGBPUSD
Fund name | Fund size | €EL weighting |
|---|---|---|
Amundi CAC 40€C40 | €999M | 4.91% |
iShares STOXX Europe 600 Health Care€EXV4 | €687M | 2.83% |
iShares MSCI Europe Health Care Sector€ESIH | €863M | 2.74% |
iShares MSCI Europe Health Care Sector£ESIH | £741M | 2.74% |
iShares MSCI Europe SRI€IESE | €3.1B | 1.82% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.